drugset / Trial / NCT06658197
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
RandomizedParallel-groupSingle-blindTreatment
Summary
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.
Timeline
- Start
- 2025-12-25
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alteplase | Protein / enzyme biologic | 0.9 mg/kg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |